L&L Immunotherapy

L&L Biopharma is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies for the treatment of cancer and other serious diseases. The company's core technology platform focuses on Bispecific Antibody Armed T cells (BATs), which involve "arming" a patient's own T cells with bispecific antibodies that target both a tumor-associated antigen and the CD3 receptor on T cells. This approach combines the precision of monoclonal antibodies with the potent cytotoxic capabilities of T cells without the need for genetic modification. L&L Biopharma is currently advancing several programs through clinical trials, targeting high-unmet-need indications such as HER2-positive breast cancer and pancreatic cancer.